Prelude Therapeutics presents new data from Phase 1 trial of PRT3789

Prelude Therapeutics (PRLD) announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class, highly selective SMARCA2 degrader designed to treat cancer patients with a SMARCA4 mutation. The data were presented at a plenary session of the 36th Annual EORTC-NCI-AACR Symposium in Barcelona, Spain. The study investigators reported, as of September 23, 2024, additional follow up data on 65 patients that were enrolled, treated, and safety evaluable. PRT3789 was generally well-tolerated through 8 dosing cohorts. The majority of adverse events reported by investigators have been mild to moderate. Overall, of the 26 advanced, heavily pre-treated NSCLC or esophageal patients with Class 1 mutations evaluable for efficacy, now with additional follow up, RECIST partial responses were confirmed in 4 patients, including 2 of 9 NSCLC patients with confirmed PRs at doses of 283 mg or higher